Nautilus Biotechnology, Inc.
NASDAQ:NAUTBiotechnology
+$0.05 today
- Market cap
- $309.51M
- Beta
- 0.75
- P/E (TTM)
- -4.9
- EPS (TTM)
- -$0.45
Volume 4.55M
Average 0.40M
NAUT Change in Working Capital
Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.
Nautilus Biotechnology, Inc.NASDAQ: NAUT
Change in Working Capital · Q1 FY2026 · quarter ended Mar 2026
Change in working capital growth accelerates
Q1 FY2026 change in working capital of $1.17M (cash outflow) rose 103.6% year over year, ahead of the -8.0% change in trailing-twelve-month change in working capital. Sequentially, it fell 22.8% from the prior quarter. Over 3 fiscal years it compounded at +65.7% a year.
Context
- Change in working capital grew in size in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +103.6% holds above the trailing-twelve-month pace of -8.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Change in Working Capital history
USD · from the cash flow
- Latest · FY2025
- (3.58M) USD
- Year-over-year change
- +34.3%
| Period | Period end | Change in Working Capital | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (3.58M) | +34.3% |
| FY2024 | 2024-12-31 | (5.46M) | -69.6% |
| FY2023 | 2023-12-31 | (3.22M) | -308.5% |
| FY2022 | 2022-12-31 | (788K) | -3481.8% |
| FY2021 | 2021-12-31 | (22K) | — |
Change in Working Capital vs competitors
How NAUT compares with its peers on the latest reported figures
- NAUT's LTM Mar 2026 change in working capital of $4.18M is the 7th largest of the 11 companies compared; the peer median is $4.83M.
- Its year-over-year change of -8.0% is the 5th highest of 11, against a peer median of -56.5%.
- Over three fiscal years its annual growth of +65.7% compares with a peer median of +44.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $36.78M | +105.8% | +162.3% | 51.7% | |
| LTM Mar 2026 | $34.76M | +146.8% | +80.5% | 50.2% | |
| LTM Mar 2026 | $31.04M | -3.9% | — | 110.0% | |
| LTM Mar 2026 | $15.14M | +208.6% | — | 750.8% | |
| LTM Mar 2026 | $8.51M | -85.7% | +46.2% | 18.8% | |
ZURAZura Bio Limited | LTM Mar 2026 | $6.07M | -215.8% | — | — |
| LTM Mar 2026 | $4.18M | -8.0% | +65.7% | — | |
| LTM Mar 2026 | $3.6M | -53.4% | +42.5% | 1601.8% | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | $3.42M | -181.2% | — | — |
| LTM Mar 2026 | $2.15M | -59.7% | -24.4% | 15.5% | |
| LTM Mar 2026 | $1.66M | -293.7% | +30.6% | — | |
| Peer median (excluding NAUT) | $4.83M | -56.5% | +44.3% | 51.7% | |
Competitors are the stored peer set for NAUT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (50.32M) | (57.92M) | (63.68M) | (70.78M) | (59M) |
| Depreciation & Amortization | 2.84M | 3.42M | 5.71M | 6.35M | 6.47M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 7.93M | 10.38M | 12.14M | 12.7M | 6.84M |
| Change in Working Capital | (22K) | (788K) | (3.22M) | (5.46M) | (3.58M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.26M | (561K) | 393K | (578K) | (69K) |
| Other Working Capital | (1.28M) | (227K) | (3.61M) | (4.88M) | (3.52M) |
| Other Non-Cash Items | 320K | (890K) | (2.66M) | (1.96M) | (1.42M) |
| Operating Cash Flow | (39.24M) | (45.81M) | (51.71M) | (59.15M) | (50.7M) |
| Capital Expenditures | (2.27M) | (2.32M) | (2.44M) | (2.12M) | (1.28M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (221.8M) | (186.59M) | (112.89M) | (86.28M) | (72.49M) |
| Sales of Investments | 85.1M | 163.18M | 71.6M | 155.41M | 108.99M |
| Other Investing Activities | 0 | 0 | 0 | (760K) | 0 |
| Investing Cash Flow | (138.96M) | (25.74M) | (43.74M) | 66.25M | 35.22M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | (7.96M) | 562K | 368K | 1.14M | 214K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 335.41M | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 327.45M | 562K | 368K | 1.14M | 214K |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 149.24M | (70.98M) | (95.08M) | 8.25M | (15.26M) |
| Free Cash Flow | (41.51M) | (48.13M) | (54.15M) | (61.27M) | (51.97M) |
Nautilus Biotechnology, Inc.
NASDAQ:NAUT
Intrinsic Alpha fair value
Locked
Current Price
$2.43
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.